Development and validation of a deep learning framework for Alzheimer’s disease classification

Alzheimer’s disease (AD) is the primary cause of dementia worldwide (1), with an increasing morbidity burden that may outstrip diagnosis and management capacity as the population ages. Current methods integrate patient history, neuropsychological testing and magnetic resonance imaging (MRI) to identify likely cases, yet effective practices remain variably-applied and lacking in sensitivity and specificity (2). Here we report an explainable deep learning strategy that delineates unique AD signatures from multimodal inputs of MRI, age, gender, and mini-mental state examination (MMSE) score. Our framework linked a fully convolutional network (FCN) to a multilayer perceptron (MLP) to construct high resolution maps of disease probability from local brain structure. This enabled precise, intuitive visualization of individual AD risk en route to accurate diagnosis. The model was trained using clinically-diagnosed AD and cognitively normal (NC) subjects from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) dataset (n=417) (3), and validated on three independent cohorts: the Australian Imaging, Biomarker & Lifestyle Flagship Study of Ageing (AIBL, n=382) (4), the Framingham Heart Study (FHS, n=102) (5), and the National Alzheimer’s Coordinating Center (NACC, n=582) (6). Model performance was consistent across datasets, with mean accuracy values of 0.966, 0.948, 0.815, and 0.916 for ADNI, AIBL, FHS and NACC, respectively. Moreover, our approach exceeded the diagnostic performance of a multi-institutional team of practicing neurologists (n=11), and high-risk cerebral regions predicted by the model closely tracked postmortem histopathological findings. This framework provides a clinically-adaptable strategy for using routinely available imaging techniques such as MRI to generate nuanced neuroimaging signatures for AD diagnosis, as well as a generalizable approach for linking deep learning to pathophysiological processes in human disease.

[1]  Rik Ossenkoppele,et al.  Predicting diagnosis and cognition with 18F-AV-1451 tau PET and structural MRI in Alzheimer's disease , 2019, Alzheimer's & Dementia.

[2]  Eric J Topol,et al.  High-performance medicine: the convergence of human and artificial intelligence , 2019, Nature Medicine.

[3]  Vijaya B. Kolachalama,et al.  Fusion of deep learning models of MRI scans, Mini–Mental State Examination, and logical memory test enhances diagnosis of mild cognitive impairment , 2018, Alzheimer's & dementia.

[4]  Geoffrey E. Hinton Deep Learning-A Technology With the Potential to Transform Health Care. , 2018, JAMA.

[5]  N. Razavian,et al.  Classification and mutation prediction from non–small cell lung cancer histopathology images using deep learning , 2018, Nature Medicine.

[6]  Philip S. Insel,et al.  Associations between tau, Aβ, and cortical thickness with cognition in Alzheimer disease , 2019, Neurology.

[7]  Sterling C. Johnson,et al.  Multimodal and Multiscale Deep Neural Networks for the Early Diagnosis of Alzheimer's Disease using structural MR and FDG-PET images , 2017, ArXiv.

[8]  Davide Castelvecchi,et al.  Can we open the black box of AI? , 2016, Nature.

[9]  Geoffrey E. Hinton,et al.  Deep Learning , 2015, Nature.

[10]  Trevor Darrell,et al.  Fully Convolutional Networks for Semantic Segmentation , 2017, IEEE Transactions on Pattern Analysis and Machine Intelligence.

[11]  Juan Carlos Fernández,et al.  Multiobjective evolutionary algorithms to identify highly autocorrelated areas: the case of spatial distribution in financially compromised farms , 2014, Ann. Oper. Res..

[12]  Frederik Barkhof,et al.  An algorithmic approach to structural imaging in dementia , 2013, Journal of Neurology, Neurosurgery & Psychiatry.

[13]  C. Jack,et al.  Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers , 2013, The Lancet Neurology.

[14]  C. Jack,et al.  Neuroimaging correlates of pathologically defined subtypes of Alzheimer's disease: a case-control study , 2012, The Lancet Neurology.

[15]  Bruce Fischl,et al.  FreeSurfer , 2012, NeuroImage.

[16]  R. Green,et al.  The Framingham Brain Donation Program: neuropathology along the cognitive continuum. , 2012, Current Alzheimer research.

[17]  W. Kukull,et al.  Accuracy of the Clinical Diagnosis of Alzheimer Disease at National Institute on Aging Alzheimer Disease Centers, 2005–2010 , 2012, Journal of neuropathology and experimental neurology.

[18]  N. Bohnen,et al.  Effectiveness and Safety of 18F-FDG PET in the Evaluation of Dementia: A Review of the Recent Literature , 2012, The Journal of Nuclear Medicine.

[19]  J. Morris,et al.  The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[20]  D. Selkoe Alzheimer's disease. , 2011, Cold Spring Harbor perspectives in biology.

[21]  Olivier Salvado,et al.  Addressing population aging and Alzheimer's disease through the Australian Imaging Biomarkers and Lifestyle study: Collaboration with the Alzheimer's Disease Neuroimaging Initiative , 2010, Alzheimer's & Dementia.

[22]  Nick C Fox,et al.  The clinical use of structural MRI in Alzheimer disease , 2010, Nature Reviews Neurology.

[23]  C. Jack,et al.  Alzheimer's Disease Neuroimaging Initiative (ADNI) , 2010, Neurology.

[24]  L H Kuller,et al.  Age, Alzheimer disease, and brain structure , 2009, Neurology.

[25]  M. Marinelli,et al.  Age matters , 2009, The European journal of neuroscience.

[26]  W. Stuart Review of recent literature , 2008, American Potato Journal.

[27]  Geoffrey E. Hinton,et al.  Visualizing Data using t-SNE , 2008 .

[28]  P. Scheltens,et al.  The significance of medial temporal lobe atrophy , 2007, Neurology.

[29]  Mike McGrath Interlending and document supply: a review of the recent literature: 59 , 2007 .

[30]  W. M. van der Flier,et al.  Hippocampal atrophy in Alzheimer disease: Age matters , 2006, Neurology.

[31]  Woodrow D. Deitrich,et al.  The National Alzheimer's Coordinating Center (NACC) Database: An Alzheimer Disease Database , 2004, Alzheimer disease and associated disorders.

[32]  Agneta Nordberg,et al.  PET imaging of amyloid in Alzheimer's disease , 2004, The Lancet Neurology.

[33]  M. Burns,et al.  Case-Control Study , 2020, Definitions.

[34]  C. DeCarli,et al.  Managing and analysing data from a large‐scale study on Framingham Offspring relating brain structure to cognitive function , 2004, Statistics in medicine.

[35]  Allison Druin,et al.  Age matters , 2002 .